Most cited papers from CSPC Pharmaceutical Group

CSPC Pharmaceutical Group

What are the most cited papers from CSPC Pharmaceutical Group?

The most cited paper from CSPC Pharmaceutical Group is "Preparation and Enhancement of Oral Bioavailability of Curcumin Using Microemulsions Vehicle" (Liandong Hu, Yanhong Jia, Feng Niu et al., 2012), with 117 citations. Next come "Highly water-soluble platinum(ii) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties" (92) and "Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery" (92).

Published TypeFieldAccess

Showing 50 of 70 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Preparation and Enhancement of Oral Bioavailability of Curcumin Using Microemulsions Vehicle Liandong Hu, Yanhong Jia, Feng Niu et al. · Journal of Agricultural and Food Chemistry	15 May 2012	117
2	Highly water-soluble platinum(ii) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties Pengxing Liu, Yanhui Lu, Xiangqian Gao et al. · Chemical Communications	2013	92
3	Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery Zhiyao He, Xi Emily Zheng, Xiao Wu et al. · International Journal of Pharmaceutics	27 Jul 2010	92
4	Enhancement of Oral Bioavailability of Curcumin by a Novel Solid Dispersion System Liandong Hu, Yanjing Shi, Jian Heng Li et al. · AAPS PharmSciTech Open access	24 Mar 2015	76
5	A preparation method for mRNA-LNPs with improved properties Cong Geng, Kefan Zhou, Yan Yan et al. · Journal of Controlled Release	16 Nov 2023	70
6	Evaluation of High-Performance Curcumin Nanocrystals for Pulmonary Drug Delivery Both In Vitro and In Vivo Liandong Hu, Dongqian Kong, Qiaofeng Hu et al. · Nanoscale Research Letters Open access	Oct 2015	70
7	Anticancer Mechanisms and Potential Anticancer Applications of Antimicrobial Peptides and Their Nano Agents Ziyi Dong, Xinyu Zhang, Qing Zhang et al. · International Journal of Nanomedicine Open access	31 Jan 2024	59
8	Design of fenofibrate microemulsion for improved bioavailability Liandong Hu, Hongyu Wu, Feng Niu et al. · International Journal of Pharmaceutics	7 Sep 2011	57
9	Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size Ruimeng Shi, Xueli Liu, Yajuan Wang et al. · Human Vaccines & Immunotherapeutics Open access	7 May 2024	42
10	Glucose conjugated platinum(II) complex: Antitumor superiority to oxaliplatin, combination effect and mechanism of action Hong Li, Xiangqian Gao, Ran Liu et al. · European Journal of Medicinal Chemistry	7 Jul 2015	41
11	A novel mRNA vaccine, SYS6006, against SARS-CoV-2 Ke Xu, Wenwen Lei, Bin Kang et al. · Frontiers in Immunology Open access	5 Jan 2023	39
12	Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer Yaru Li, Ziru Sun, Yujun Cui et al. · Bioorganic Chemistry	10 Jan 2021	36
13	Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents Xiangqian Gao, Shengnan Liu, Yunli Shi et al. · European Journal of Medicinal Chemistry	17 Sep 2016	30
14	2-Deoxyglucose conjugated platinum (II) complexes for targeted therapy: design, synthesis, and antitumor activity Qian Mi, Yuru Ma, Xiangqian Gao et al. · Journal of Biomolecular Structure and Dynamics	2 Nov 2015	29
15	Heat shock cognate protein 70 gene is required for prevention of apoptosis induced by WSSV infection Feng Yan, Ding Xia, Jia Hu et al. · Archives of Virology	10 May 2010	28
16	Oxidative DNA damage and multi-organ pathologies in male mice subchronically treated with aflatoxin B1 Hongyuan Zhou, Jiaman Wang, Liang Ma et al. · Ecotoxicology and Environmental Safety	17 Oct 2019	22
17	Design, Synthesis of Novel Platinum(II) Glycoconjugates, and Evaluation of Their Antitumor Effects Jianbin Han, Xiangqian Gao, Ran Liu et al. · Chemical Biology & Drug Design	26 Dec 2015	21
18	Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer Shen Zhao et al. · Nature Communications Open access	12 Jun 2023	20
19	An Unrevealed Molecular Function of Corannulene Buckybowl Glycoconjugates in Selective Tumor Annihilation by Targeting the Cancer‐Specific Warburg Effect Shengnan Liu, Ziru Sun, Min Liang et al. · Advanced Science Open access	7 Mar 2022	20
20	Enhanced antitumor efficacy of folate targeted nanoparticles co-loaded with docetaxel and curcumin Liandong Hu, Saixi Pang, Qiaofeng Hu et al. · Biomedicine & Pharmacotherapy	2 Sep 2015	20
21	An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index Xiwu Hui, Can Yuan, Weirong Cao et al. · OncoTargets and Therapy Open access	Apr 2022	19
22	A GLUT1 inhibitor-based fluorogenic probe for Warburg effect-targeted drug screening and diagnostic imaging of hyperglycolytic cancers Shunjie Zhang, Xinyu Wang, Ru Zhang et al. · Analytica Chimica Acta	30 Apr 2021	17
23	Development of a long-acting intramuscularly injectable formulation with nanosuspension of andrographolide Liandong Hu, Chenchen Yang, Dongqian Kong et al. · Journal of Drug Delivery Science and Technology	9 Sep 2016	16
24	Glucose-Responsive Microspheres as a Smart Drug Delivery System for Controlled Release of Insulin Jiaojiao Yu, Qiongyan Wang, Haofan Liu et al. · European Journal of Drug Metabolism and Pharmacokinetics	Nov 2019	15
25	Levels of lncRNA GAS5 in Plasma of Patients with Severe Traumatic Brain Injury: Correlation with Systemic Inflammation and Early Outcome Jin Lei, Xiao Zhang, Rui Tan et al. · Journal of Clinical Medicine Open access	9 Jun 2022	14
26	A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors Zhuang Kang, Shenglan Li, Yi Lin et al. · Investigational New Drugs Open access	8 Mar 2023	13
27	A novel mRNA rabies vaccine as a promising candidate for rabies post-exposure prophylaxis protects animals from different rabies viruses Pengcheng Yu, Dan Mo, Ying He et al. · Microbial Pathogenesis	Nov 2023	12
28	Glycocalixarene with luminescence for Warburg effect-mediated tumor imaging and targeted drug delivery Yang Li, Shengnan Liu, Min Liang et al. · Chemical Communications	2021	11
29	Morphology evolution of lipid nanoparticle discovered by small angle neutron scattering Yuqing Li, Changli Ma, Zehua Han et al. · Giant Open access	25 Jul 2024	10
30	The treatment of hepatocellular carcinoma with SP94 modified asymmetrical bilayer lipid-encapsulated Cu(DDC)2 nanoparticles facilitating Cu accumulation in the tumor Hao Liu, Yihan Kong, Xue Liang et al. · Expert Opinion on Drug Delivery	3 Dec 2022	8
31	Monoglycocalix[4]arene-based nanoparticles for tumor selective drug delivery via GLUT1 recognition of hyperglycolytic cancers Lijuan Zhang, Shengnan Liu, Yang Li et al. · Organic & Biomolecular Chemistry	2022	8
32	Anticancer drug R&D landscape in China Shen Zhao, Hongyun Zhao, Cheng Lv et al. · Journal of Hematology & Oncology Open access	13 May 2020	8
33	Extraction and detection of sulfonamide antibiotics in milk using magnetic solid-phase adsorbent based on molecular mechanics and DFT calculations Yuanke Zhang, Yuanke Zhang, Siqi Wang et al. · Microchemical Journal	12 Sep 2024	7
34	First- and Second-Generation Nucleoside Triphosphate Prodrugs: TriPPPro-Compounds for Antiviral Chemotherapy Xiao Dong Jia, Chenglong Zhao, Chris Meier Book chapter	2023	6
35	Persistent immune response: Twice tumor exfoliation induced by sialic acid–modified vincristine sulfate liposomes Xinyang Yan, Xin Gao, Xiaoya Li et al. · International Journal of Pharmaceutics	7 Dec 2022	6
36	Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study Diaozhu Lin, Huisheng Xiao, Kexu Yang et al. · BMC Medicine Open access	28 May 2024	5
37	137MO Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study) Li Zhang, Wenfeng Fang, Shen Zhao et al. · ESMO Open Open access	Mar 2024	5
38	Ryanodine receptor-targeting small molecule fluorescent probes enables non-isotopic labeling and efficient drug screening for green insecticides Zizhen Li, Heng Jiang, Shengnan Liu et al. · Analytica Chimica Acta	26 Feb 2020	4
39	The in Vivo Profile of CT133, a Potent, Well Tolerated, and Selective CRTH2 Antagonist for the Treatment of Allergic Asthma and Rhinitis Dan Huai Guo · Journal of Allergy and Clinical Immunology Open access	Feb 2015	4
40	Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial Jing Zuo et al. · 癌症：英文版 Open access	23 Jul 2024	3
41	7MO Becotarug (JMT101) and osimertinib (Osi) in patients (pts) with platinum-pretreated EGFR exon 20 insertion-mutated (ex20ins) non-small cell lung cancer (NSCLC): Final overall survival (OS) and subgroup analyses from the BECOME phase II study L. Zhang, W.F. Fang, Y. Huang et al. · ESMO Open Open access	17 Mar 2026	2
42	SYHA1813 , A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study Zhuang Kang, Shenglan Li, Liang Wang et al. · Annals of Clinical and Translational Neurology Open access	22 Aug 2025	2
43	Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study Hairong Xu et al. · Nature Communications Open access	5 Nov 2024	2
44	506MO A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma Wenbin Li, Z. Kang, Zhen Wu et al. · Annals of Oncology Open access	Oct 2023	2
45	The randomized, single‐ and multiple‐ ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects Shan Jing, Wenfang Liu, Kexu Yang et al. · Clinical and Translational Science Open access	9 Dec 2022	2
46	625MO Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trial Ying Huang, Tao Wu, Yunfei Hu et al. · Annals of Oncology Open access	Sep 2022	2
47	Preparation, characterization, and in vivo evaluation of injectable long-acting curcumin microcrystal Liandong Hu, Dongqian Kong, Qiaofeng Hu et al. · Particulate Science And Technology	2 Feb 2017	2
48	Real-Time Process Monitoring Ammonolysis of Oligonucleotides with Online FTIR Spectroscopy R. Wang, Liming Xu, Yifan Yang et al. · Organic Process Research & Development	4 Mar 2026	1
49	Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes Wenfang Liu, Kexu Yang, Yang Lin et al. · Clinical Pharmacokinetics Open access	19 Apr 2025	1
50	Optimizing Rabies mRNA Vaccine Efficacy: Role of RABV-G Structural Domains and Heterologous Prime-Boost Immunization Strategies Dongdong Li, Xuan Wang, Gaotian Li et al. · Research Square PreprintOpen access	12 Nov 2024	1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.